Search

Novavax Inc

Fechado

SetorSaúde

8.05 -1.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.91

Máximo

8.1

Indicadores-chave

By Trading Economics

Rendimento

-44M

-53M

Vendas

-83M

57M

P/E

Médio do Setor

3.112

57.002

EPS

-0.32

Margem de lucro

-94.16

Funcionários

749

EBITDA

-39M

-40M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+62.78% upside

Dividendos

By Acuity

Próximos Ganhos

5 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

83M

1.3B

Abertura anterior

9.16

Fecho anterior

8.05

Sentimento de Notícias

By Acuity

36%

64%

130 / 340 Ranking em Healthcare

Novavax Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de ago. de 2026, 23:26 UTC

Novavax Inc. shares are trading roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of the one-month range.

13 de ago. de 2026, 19:16 UTC

Novavax Inc. shares are higher today, maintaining strength above the 20-day moving average despite rising initial jobless claims reported by the Labor Department.

12 de ago. de 2026, 23:31 UTC

Novavax Inc. shares are lower in after-market trading, reflecting a weaker trend despite earlier gains. The stock remains above its 20-day moving average.

11 de ago. de 2026, 23:51 UTC

Novavax Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average within its one-month trading range.

10 de ago. de 2026, 23:46 UTC

Novavax Inc. shares are lower in after-market trading, showing some volatility since Monday's close and remaining within the middle of their one-month trading range.

7 de ago. de 2026, 19:36 UTC

News

Novavax Inc shares are higher today, supported by $57 million in second-quarter revenue and ongoing discussions with Sanofi on a COVID-19/influenza vaccine.

6 de ago. de 2026, 23:01 UTC

News

Novavax Inc expects 2026 revenue of $235 million to $275 million. Shares are trading higher in after-market hours following the earnings call.

5 de ago. de 2026, 23:01 UTC

Novavax shares are higher in after-market trading, though they remain below the 20-day moving average amid weaker-than-expected U.S. job growth data.

4 de ago. de 2026, 23:36 UTC

Novavax Inc. shares are higher in after-market trading, despite remaining below their 20-day moving average. Broader market sentiment may support this upward movement.

3 de ago. de 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 de jul. de 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 de jul. de 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 de jul. de 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 de jul. de 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 de jul. de 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 de jul. de 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 de jul. de 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 de jul. de 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 de jul. de 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 de jul. de 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Comparação entre Pares

Variação de preço

Novavax Inc Previsão

Preço-alvo

By TipRanks

62.78% parte superior

Previsão para 12 meses

Média 13.25 USD  62.78%

Máximo 19 USD

Mínimo 7 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Novavax Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

2

Comprar

1

Manter

1

Vender

Sentimento

By Acuity

130 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat